Literature DB >> 27811604

Viral Infections in Juvenile Myelomonocytic Leukemia: Prevalence and Clinical Implications.

Atsushi Manabe1, Tetsu Yoshimasu, Yasuhiro Ebihara, Hiroshi Yagasaki, Mika Wada, Kumiko Ishikawa, Junichi Hara, Kenichi Koike, Hiroshi Moritake, Yong Dong Park, Kohichiro Tsuji, Tatsutoshi Nakahata.   

Abstract

OBJECTIVES: Viral infections may complicate the diagnosis of juvenile myelomonocytic leukemia (JMML) in a substantial proportion of patients, but this possibility has not been tested in a prospective study. The authors therefore measured the cellular expression of the MxA protein, a reliable marker of viral infection, at diagnosis in children with JMML to estimate the prevalence of such infections.
METHODS: Eighteen children, aged 1 to 69 months, who met the diagnostic criteria of the International JMML Working Group were prospectively studied. MxA expression was assessed by flow cytometric analysis of peripheral blood mononuclear cells stained with an antihuman MxA antibody. All data were obtained through the MDS Committee of the Japanese Society of Pediatric Hematology.
RESULTS: Twelve patients (67%) had elevated levels of the MxA protein, with rotavirus, RS virus, or CMV infection documented in three of these patients. Although none of the patients had primary Epstein-Barr virus (EBV) infection, reactivation of the virus was strongly suspected in four children, including two with monosomy 7, each having increased levels of MxA. Southern blot analysis revealed monoclonal integration of the EBV genome into bone marrow mononuclear cells from one of these patients. There was no discernible correlation between increases in the marker protein and the presenting features or course of the disease.
CONCLUSIONS: Viral infection may be present in two thirds of children with newly diagnosed JMML, but it does not constitute a basis for revising clinical management. The possibility that EBV or other viruses contribute to JMML pathogenesis by stimulating pre-exiting malignant clones warrants further investigation.

Entities:  

Year:  2004        PMID: 27811604     DOI: 10.1097/01.mph.0000140653.50344.5c

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

Review 1.  Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.

Authors:  Nao Yoshida; Sayoko Doisaki; Seiji Kojima
Journal:  Paediatr Drugs       Date:  2012-06-01       Impact factor: 3.022

Review 2.  Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations.

Authors:  Ayami Yoshimi; Seiji Kojima; Naoto Hirano
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

3.  Diagnostic dilemma of JMML coexisting with CMV infection.

Authors:  Kriti Puri; Prashant Singh; Rashmi Ranjan Das; Rachna Seth; Ritu Gupta
Journal:  Indian J Pediatr       Date:  2010-12-31       Impact factor: 5.319

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.